This is a free excerpt of a hot topic update from our PracticeView monitoring service. Click here to learn more or subscribe to PracticeView.
Background
Rather than short-changing research & development activities in light of shrinking budgets, pharmaceutical companies are looking to streamline their process for new product development. Drug discovery outsourcing is becoming more popular, and companies are encouraging more collaborative approaches to innovation. R&D tax credits continue to serve as critical incentives for drug development, and government initiatives strive to support strong infrastructure for entrepreneurs and start-up companies, as well as established pharmaceutical businesses.
Implications
Subscribers to our PracticeView monitoring service receive detailed commentary on the implications of this trend and/or emerging news.
Client Discussion Points
Below is an example question which subscribers of our PracticeView monitoring service receive. This type of question can become a talking point to be used by your firm and its professionals to stimulate discussions with clients and/or prospects.
- What strategic prospects can pharmaceutical companies explore in order to sustain innovation in drug development?
Resources & Commentary
Subscribers receive a number of direct links to interesting/authoritative articles on a particular topic and/or trend. Below is an example of a direct link which subscribers of our PracticeView monitoring service receive.
Click here to learn more or subscribe to PracticeView.
